VIGANO PAUL R sold $8.0M of AVAH (indirect holdings)

VIGANO PAUL R sold 1,000,000 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $8.00 ($8.00M total) across 3 trades on 2026-06-24.

Original reporting
SEC EDGAR · VIGANO PAUL R
Published Jun 26, 2026, 5:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVAH
Neutral
medium confidence
Mentioned
$AVAH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHNeutralLow
01

Why it matters

A large insider sale can modestly pressure sentiment, but without accompanying fundamental news it usually has limited trading impact.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing.

03

What to watch

No 10b5-1 plan is stated, but the filing also doesn’t clarify whether the remaining holdings will be sold soon or whether other insiders are buying.

Relevance 6/10Novelty 5/10Timing: after-hours/filing update on 2026-06-26 for a 2026-06-24 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Aveanna Healthcare Holdings, Inc.

Company-level read

Ticker impact

$AVAHNeutralMedium confidence
Context

Aveanna Healthcare Holdings disclosed a 10% owner indirect open-market sale of 1,000,000 shares at $8.00 on 2026-06-24 via Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless follow-on selling continues.

Evidence & confidence

Form 4 insider sales are common and this disclosure lacks a stated 10b5-1 plan, but it also does not include fundamentals, contracts, or regulatory developments.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory or demand signal.

None indicated.

None indicated.

Counterpoint

The sale is indirect and may reflect diversification or pre-planned liquidity needs rather than a bearish view on the business.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    Subject of the Form 4 insider transaction; 10% owner reported an indirect open-market sale.

  • VIGANO PAUL R

    10% owner who sold 1,000,000 shares indirectly at $8.00/share across three trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.